This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bagis, T. Articles by Haydardedeoglu, B. Search for Related Content PubMed PubMed Citation Articles by Bagis, T. Articles by Haydardedeoglu, B.

The Effects of Short-Term Medroxyprogesterone Acetate and Micronized Progesterone on Glucose Metabolism and Lipid Profiles in Patients with Polycystic Ovary Syndrome: A Prospective Randomized Study

Baskent University Faculty of Medicine, Department of Obstetrics and Gynecology (T.B., H.B.Z., E.T., E.B.K., B.H.), and Endocrinology and Metabolism Division (A.G.), 01170 Adana, Turkey

Address all correspondence and requests for reprints to: Tayfun Bagis, M.D., Assistant Professor, Obstetrics and Gynecology Department, Guzelyali Mahalle, Adnan Kahveci Bulvari, Bilgin Apartman, Kat:6 No. 11, Seyhan-Adana, Turkey. E-mail: bagistayfun{at}hotmail.com.

Abstract

In this prospective, randomized study we determined 10-d effects of medroxyprogesterone acetate (MPA) and micronized progesterone (MP) either orally or per vaginally on hormonal parameters, glucose metabolism and lipid profiles in patients with polycystic ovary syndrome (PCOS). Twenty-eight consecutive women with PCOS were randomized to receive 10-d MPA, oral MP, or vaginal MP. Hormonal parameters, insulin levels, oral glucose tolerance test, lipid profiles, and homeostasis model assessment and quantitative insulin sensitivity check indexes were assessed in all groups before and after treatment. Oral MPA and oral MP decreased LH (15.64 ± 13.17 to 7.27 ± 4.35 IU/liter, P = 0.028, and 18.85 ± 11.86 to 10.49 ± 6.48 IU/liter, P = 0.009, respectively) and total testosterone (5.85 ± 2.80 to 3.40 ± 1.72 nmol/liter, P = 0.013, and 5.29 ± 2.98 to 3.43 ± 2.10 nmol/liter, P = 0.037, respectively) levels. Hormonal parameters did not change with vaginal MP. Basal insulin (123.42 ± 97.50 to 87.38 ± 48.68 pmol/liter; P = 0.021) and homeostasis model assessment levels decreased, and quantitative insulin sensitivity check index increased significantly in the oral MPA group. Low density lipoprotein cholesterol and lipoprotein (a) levels decreased only in the MPA group. In conclusion, short-term oral MP and especially oral MPA might ameliorate insulin sensitivity in patients with PCOS. Vaginal MP has no effect on glucose metabolism and lipid profiles. LH, total testosterone, and insulin levels may be affected from the short-term progesterone treatment.

This article has been cited by other articles:

				S. Palomba, A. Falbo, T. Russo, F. Manguso, A. Tolino, F. Zullo, P. De Feo, and F. Orio Jr. Insulin Sensitivity after Metformin Suspension in Normal-Weight Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3128 - 3135. [Abstract] [Full Text] [PDF]

				C. Meyer, B. P. McGrath, and H. J. Teede Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome Diabetes Care, March 1, 2007; 30(3): 471 - 478. [Abstract] [Full Text] [PDF]

				D. J. Toufexis, C. Davis, A. Hammond, and M. Davis Progesterone Attenuates Corticotropin-Releasing Factor-Enhanced But Not Fear-Potentiated Startle via the Activity of Its Neuroactive Metabolite, Allopregnanolone J. Neurosci., November 10, 2004; 24(45): 10280 - 10287. [Abstract] [Full Text] [PDF]